Table 1 Clinical characteristics of the study cohort at baseline (N = 92).
Characteristics | No. of patients (%) |
|---|---|
Age, median (range) | 57 (28–74) |
Sex | |
 Male | 59 (64.1) |
 Female | 33 (35.9) |
Histological type | |
 Adenocarcinoma | 78 (84.8) |
 Non-adenocarcinoma | 14 (15.2) |
Smoking status | |
 Smokers | 41 (44.6) |
 Non-smokers | 51 (55.4) |
ECOG PS | |
 0–1 | 63 (68.5) |
 ≥ 2 | 29 (31.5) |
CNS symptoms | |
 Yes | 49 (53.3) |
 No | 43 (46.7) |
Brain tumor number | |
 1–3 | 31 (33.7) |
 ≥ 4 | 61 (66.3) |
Maximum brain tumor size (mm) | |
 Median (range) | 19.0 (5.0-47.4) |
Thoracic stage a | |
 I–II | 12 (13.0) |
 IIIA | 29 (31.5) |
 IIIB | 40 (43.5) |
 IIIC | 11 (12.0) |
Distant metastases | |
 Liver | 11 (12.0) |
 Bone | 45 (48.9) |
 Adrenal gland | 19 (20.7) |
Gene mutation | |
 EGFR mutation | 44 (47.8) |
 ALK rearrangement | 3 (3.3) |
 EGFR/ALK wild-type | 45(48.9) |
Lung-molGPA b | |
 0–1 | 8 (8.7) |
 1.5–2 | 23 (25.0) |
 2.5–3 | 44 (47.8) |
 3.5–4.5 | 17 (18.5) |
First-line treatment | |
 Chemotherapy | 35 (38.0) |
 Immunotherapy | 10 (10.9) |
 Tyrosine kinase inhibitors (TKIs) | 47 (51.1) |
With tumor tissues | 58 (63.0) |
Primary lung tumors | 38 (41.3) |
Lymph nodes | 20 (21.7) |
Without tumor tissues | 34 (37.0) |